MedTrace Logo

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

NCT05155189 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-01-21

No results posted yet for this study

Summary

A study that aimed to assess the safety and anti-tumor activity of CCAR031 injection in unresectable HCC patients.

Conditions

Interventions

BIOLOGICAL

C-CAR031

Targeting GPC3 armored CART cell injection (C-CAR031)

DRUG

Lenvatinib

Tyrosine kinase inhibitors

DRUG

Regorafenib (BAY 73-4506)

Tyrosine kinase inhibitors

DRUG

Durvalumab

Immune checkpoint inhibitors, ICIs

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-21
Primary Completion
2026-05-31
Completion
2041-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05155189 on ClinicalTrials.gov